Fibroblasts and Induced Pluripotent Stem Cells (iPSC) for Parkinson’s Disease Research:
The NINDS has created a fibroblast and induced pluripotent stem cell (iPSC) resource for Parkinson’s Disease research that is available through the NINDS repository at the Coriell Institute for Medical Research. Fibroblast lines currently available for distribution include: alpha-synuclein triplication, LRRK2 mutations, parkin mutations, PINK1 mutations, GBA and others including fibroblast lines for idiopathic PD patients. Available iPSC lines currently include alpha-synuclein triplication, LRRK2 and parkin mutations. Control lines are also available.
Please note the following NINDS policy on applications proposing development of iPSC lines:
Proposals including the development of induced pluripotent stem cell (iPSC) lines already represented in the NINDS repository are not permitted. Investigators proposing to develop isogenic lines should consult the NINDS program officer prior to submission. New iPSC lines developed must meet the following criteria: 1) patient consent must allow for broad data and resource sharing (academic and industry investigators) including use for genetic studies, wherein part or all of the genome may be sequenced; 2) the institution/facility must have licenses for iPSC and related (e.g. genome editing, reporter use) technologies that allow deposition and broad distribution of resulting iPCS lines through the NINDS repository); 3) for iPSC lines currently available through the NINDS repository, gene correction experiments must be done in these lines; 4) a timeline must be provided for banking of available iPSC lines with the NINDS repository; 5) all iPSC lines derived must be characterized for sterility and be free of mycoplasma contamination, have normal karyotypes, normal growth rates and colony morphology, demonstrated pluripotency through a pluritest, scorecard test or equivalent test, demonstrate surface antigen expression of stem cell markers, demonstrated ability to form embryoid bodies and demonstrated transgene silencing for the reprogramming factors used. For gene correction/gene editing projects, investigators will be asked to whole genome sequence the original and edited clones and deposit this data with the NINDS Parkinson’s Disease Biomarkers Program (PDBP) Data Management Resource (DMR).
Point of Contact: Margaret Sutherland, Ph.D., Program Director
Last updated March 12, 2014